Status:
UNKNOWN
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Prurigo Nodularis
Itch
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are 1. whether tofacitinib is effective in treating prurig...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- age ≥18 years old;
- patients diagnosed with PN with a duration of more than 6 months;
- presence of at least 10 pruritic nodules;
- a Worst Itch-Numeric Rating Scale (WI-NRS) score ≥7 one week before study;
- a history of more than 2 weeks of ineffective topical glucocorticoid treatment or antihistamine therapy;
- signed informed consent and cooperated with the follow up and complied the study protocol.
- Exclusion criteria:
- current used of biologic, systemic glucocorticoid or immunosuppressive agents; past used of jak inhibitors;
- were pregnant or lactating;
- abnormal findings for patients' complete blood count, liver functions, and kidney function tests;
- presence of any infection or inflammatory; presence of active tumors or an increased risk of tumor complications；
- systemic comorbidities that could interfere with or complicate study assessments.
- those experiencing atopic dermatitis within 6 months were excluded from this study.
Exclusion
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06201715
Start Date
May 1 2024
End Date
December 30 2025
Last Update
April 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China, 310009